As prices continue to drop and technology continues to improve, the purchase of a next-generation sequencing (NGS) platform is now a reality for most research laboratories. Once you have purchased a platform, however, how do you maximize the greatest potential for your investment? Realizing this potential requires efficient workflow strategies, careful experimental design, comprehensive targeted enrichment technologies, data analysis, management, and integration, in addition to maintaining your platform and people management all at maximum production. The central theme at Cambridge Healthtech Institute's Sequencing Strategies for Success is efficient utilization of your NGS platform. Sessions will focus on common bottlenecks, case studies, real-world experiences and solutions from experienced NGS users.

• Lisa D. White, Ph.D., Associate Professor, Molecular and Human Genetics, Baylor College of Medicine
• Nicholas P. Ambulos, Jr., Ph.D., Associate Professor, Microbiology and Immunology; Executive Director, School of Medicine Core Facilities; Director, Genomics Core Facility, University of Maryland School of Medicine
• Kevin V. Shianna, Ph.D., Senior Vice President, Sequencing Operations, New York Genome Center
• Joseph Boland, Director, Research and Development, Cancer Genomics Research Laboratory, National Cancer Institute, National Institutes of Health
• Yijun Ruan, Ph.D., Professor and Director, Genome Sciences, The Jackson Laboratory for Genomic Medicine
• Hojoong Kwak, M.D., Research Scientist, Molecular Biology and Genetics, John Lis Laboratory, Cornell University
• Betsy J. Barnes, Ph.D., Associate Professor, Biochemistry and Molecular Biology, New Jersey Medical School University Hospital Cancer Center, University of Medicine and Dentistry New Jersey
• Mats Ljungman, Ph.D., Associate Professor, Radiation Oncology, University of Michigan
• Philippe Lefrancois, Ph.D., Faculty of Medicine, University of Montreal
• Anastasios Vourekas, Ph.D., Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
• Matthew Keyser, Next-Gen Applications Scientist, DNASTAR, Inc.
• David Galas, Ph.D., Principal Scientist, Pacific Northwest Diabetes Research Institute
• Sherman Weissman, Ph.D., Sterling Professor of Genetics and Medicine, Yale University School of Medicine
• Yaniv Erlich, Ph.D., Principal Investigator, Whitehead Fellow, Whitehead Institute for Biomedical Research